Giuseppe Uras
Development of p-Tau Differentiated Cell Model of Alzheimer’s Disease to Screen Novel Acetylcholinesterase Inhibitors
Uras, Giuseppe; Li, Xinuo; Manca, Alessia; Pantaleo, Antonella; Bo, Marco; Xu, Jinyi; Allen, Stephanie; Zhu, Zheying
Authors
Xinuo Li
Alessia Manca
Antonella Pantaleo
Marco Bo
Jinyi Xu
STEPHANIE ALLEN stephanie.allen@nottingham.ac.uk
Professor of Pharmaceutical Biophysics
ZHEYING ZHU Zheying.Zhu@nottingham.ac.uk
Associate Professor in International Pharmacy and Traditional Medicines
Contributors
Jose Luis Zugaza
Editor
Abstract
Alzheimer’s disease (AD) is characterized by an initial accumulation of amyloid plaques and neurofibrillary tangles, along with the depletion of cholinergic markers. The currently available therapies for AD do not present any disease-modifying effects, with the available in vitro platforms to study either AD drug candidates or basic biology not fully recapitulating the main features of the disease or being extremely costly, such as iPSC-derived neurons. In the present work, we developed and validated a novel cell-based AD model featuring Tau hyperphosphorylation and degenerative neuronal morphology. Using the model, we evaluated the efficacy of three different groups of newly synthesized acetylcholinesterase (AChE) inhibitors, along with a new dual acetylcholinesterase/glycogen synthase kinase 3 inhibitor, as potential AD treatment on differentiated SH-SY5Y cells treated with glyceraldehyde to induce Tau hyperphosphorylation, and subsequently neurite degeneration and cell death. Testing of such compounds on the newly developed model revealed an overall improvement of the induced defects by inhibition of AChE alone, showing a reduction of S396 aberrant phosphorylation along with a moderate amelioration of the neuron-like morphology. Finally, simultaneous AChE/GSK3 inhibition further enhanced the limited effects observed by AChE inhibition alone, resulting in an improvement of all the key parameters, such as cell viability, morphology, and Tau abnormal phosphorylation.
Citation
Uras, G., Li, X., Manca, A., Pantaleo, A., Bo, M., Xu, J., …Zhu, Z. (2022). Development of p-Tau Differentiated Cell Model of Alzheimer’s Disease to Screen Novel Acetylcholinesterase Inhibitors. International Journal of Molecular Sciences, 23(23), Article 14794. https://doi.org/10.3390/ijms232314794
Journal Article Type | Article |
---|---|
Acceptance Date | Nov 16, 2022 |
Online Publication Date | Nov 26, 2022 |
Publication Date | Nov 26, 2022 |
Deposit Date | Nov 28, 2022 |
Publicly Available Date | Nov 28, 2022 |
Journal | International Journal of Molecular Sciences |
Print ISSN | 1661-6596 |
Electronic ISSN | 1422-0067 |
Publisher | MDPI |
Peer Reviewed | Peer Reviewed |
Volume | 23 |
Issue | 23 |
Article Number | 14794 |
DOI | https://doi.org/10.3390/ijms232314794 |
Keywords | Alzheimer; AChE; GSK3-β; inhibitors; Tau; hyperphosphorylation |
Public URL | https://nottingham-repository.worktribe.com/output/14307156 |
Publisher URL | https://www.mdpi.com/1422-0067/23/23/14794 |
Files
Development of p-Tau Differentiated Cell Model
(6.5 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Engineered Polymer–Transferrin Conjugates as Self-Assembling Targeted Drug Delivery Systems
(2017)
Journal Article